Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
Mankind Pharma Ltd is a prominent pharmaceutical company in India, engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations. It operates within the pharmaceutical sector. The company was incorporated in the year 1991 and began its operations in 1995. Over the years, it has grown to become one of the top pharmaceutical companies in India, known for its commitment to quality and affordability. The headquarters of Mankind Pharma is located in New Delhi, India. Mankind Pharma's main products include a wide range of pharmaceuticals and consumer healthcare products. Read More...
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 10,615.63 | 8,878 | 7,977.58 | 6,385.38 | 5,975.65 |
Total Expenses | 8,231.49 | 7,219.18 | 6,017.43 | 4,705.45 | 4,549.45 |
Profit Before Tax | 2,399.36 | 1,671.24 | 1,974.60 | 1,691.61 | 1,437.73 |
Profit After Tax | 1,941.77 | 1,309.68 | 1,452.96 | 1,293.03 | 1,056.15 |
Operating Profit after Depreciation | 2,417.68 | 1,703.28 | 2,018.76 | 1,700.08 | 1,448.17 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 4,614.65 | 4,302.24 | 3,614.37 | 1,659.28 | 1,597.73 |
Total Non Current Assets | 5,395.03 | 5,387.58 | 4,740.92 | 2,465.99 | 2,251.07 |
Total Current Assets | 6,568.23 | 4,327.87 | 4,406.82 | 3,906.64 | 2,822.22 |
TOTAL ASSETS | 11,963.25 | 9,715.45 | 9,147.74 | 6,372.63 | 5,073.28 |
Total Shareholder's Fund | 9,363.09 | 7,435.22 | 6,155.23 | 4,722 | 3,485.31 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 2,152.45 | 1,813.30 | 919.78 | 1,137.24 | 1,069.71 |
Net Cash used in Investing Activities | -2,080.52 | -1,051.81 | -1,368.67 | -1,221.84 | -435.55 |
Net Cash used in Financing Activities | 5.27 | -739.73 | 604.62 | -7.81 | -530.74 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 9,531.45 | 8,289.94 | 7,690.04 | 5,677.68 | 4,888.26 |
Total Expenses | 7,271.88 | 6,727.10 | 5,818.60 | 4,237.47 | 3,623.34 |
Profit Before Tax | 2,259.57 | 1,562.84 | 1,871.44 | 1,440.21 | 1,264.92 |
Profit After Tax | 1,823.41 | 1,248.26 | 1,389.42 | 1,084.37 | 958.23 |
Operating Profit after Depreciation | 2,274.14 | 1,590.58 | 1,918.56 | 1,448.19 | 1,275.54 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 3,473.77 | 3,193.85 | 2,952.58 | 982.01 | 942.95 |
Total Non Current Assets | 5,927.30 | 5,854.21 | 5,122.99 | 2,790.35 | 2,582.50 |
Total Current Assets | 5,490.41 | 3,516.91 | 3,815.71 | 3,089.98 | 1,948.60 |
TOTAL ASSETS | 11,417.71 | 9,371.12 | 8,938.70 | 5,880.33 | 4,531.11 |
Total Shareholder's Fund | 9,623.81 | 7,783.91 | 6,540.45 | 4,734.27 | 3,651.45 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 1,982.97 | 1,798.99 | 821.44 | 983.38 | 959.61 |
Net Cash used in Investing Activities | -1,919.22 | -1,040.61 | -1,360.27 | -1,127.16 | -395.68 |
Net Cash used in Financing Activities | -8.68 | -710.41 | 578.63 | 88.87 | -558.91 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 3,230 | 3,076.51 | 2,893.42 | 2,441.10 | 2,606.95 |
Total Expenses | 2,400.20 | 2,226.47 | 2,211.66 | 1,850 | 2,000.45 |
Profit Before Tax | 497.33 | 849.32 | 667.62 | 571.57 | 562.32 |
Profit After Tax | 384.52 | 658.88 | 543.07 | 476.59 | 459.81 |
Operating Profit after Depreciation | 910.56 | 962.04 | 786.27 | 685.64 | 681.23 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 2,396.57 | 2,529.74 | 2,403.26 | 1,996.55 | 2,209.21 |
Total Expenses | 1,655.64 | 1,777.71 | 1,831.06 | 1,481.38 | 1,636.04 |
Profit Before Tax | 524.25 | 802.44 | 606.61 | 536.32 | 570.82 |
Profit After Tax | 416.38 | 634.43 | 513.49 | 454.17 | 487.08 |
Operating Profit after Depreciation | 810.75 | 889.78 | 696.27 | 622.60 | 664.77 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Mankind Pharma Ltd | ₹2,396.85 | ₹98,886.10 |
Sun Pharmaceuticals Industries Ltd | ₹1,704.65 | ₹4,09,002.64 |
Divis Laboratories Ltd | ₹5,836.45 | ₹1,54,939.41 |
Cipla Ltd | ₹1,459.05 | ₹1,17,834.93 |
Torrent Pharmaceuticals Ltd | ₹3,011.50 | ₹1,01,918.27 |
Dr Reddys Laboratories Ltd | ₹1,195.85 | ₹99,784.59 |
Mankind Pharma shed 2.76% to Rs 2,560.05 after the company's consolidated net profit declined 16.2% to Rs 380.23 crore in Q3 FY25 as against Rs 453.76 crore posted in Q3 FY24.
24 Jan 2025, 12:12 pm
On 23 January 2025
13 Jan 2025, 05:30 pm
20 Dec 2024, 02:17 pm
Mankind Pharma said that its board has approved the closure of the issue for the qualified institutions placement of equity shares of the company on Thursday, 19 December 2024.
20 Dec 2024, 11:52 am
Mankind Pharma added 1.17% to Rs 2722.15 after the company informed that its board has approved the opening of issue of qualified institutional placement (QIP) of equity shares with the floor price of Rs 2,616.55 per equity share.
17 Dec 2024, 10:07 am
View More